Regen BioPharma Inc. RGBP

What this company does

We intend to engage primarily in the development of regenerative medical applications which we intend to license, develop internally or acquire outright from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. HemaXellarate is a cellular composition of autologous stromal vascular fraction derived from adipose tissue. dCellVax is comprised of autologous dendritic cells which have been treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme. DuraCar is comprised of CAR-T cells which have been treated with an shRNA targeting the gene NR2F6. We have identified and patented a series of small molecules which can both activate and inhibit NR2F6.

Written from the business description in Regen BioPharma, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 30 December 2025. Every sentence was checked against that document before publication.